Sinovac Biotech, Overview
Valuation check: SVA's PEG ratio is 11.38, above the Healthcare sector average of 2.56.
Get informed when a big investor buys or sells
+ Follow11.38
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for SVA is 11.38. That is above the Healthcare sector average of 2.56. Investors often review this figure alongside Sinovac Biotech,'s historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, SVA currently prints 11.38 for PEG ratio, while the sector average sits near 2.56. That is roughly 344.7% above the sector mean. Large gaps often invite a closer look at Sinovac Biotech,'s growth, margins, and balance sheet.
A PEG ratio of 11.38 for Sinovac Biotech, is not 'good' or 'bad' on its own. Compare it with the peer average (2.56) and with SVA's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting SVA's PEG ratio (11.38), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Sinovac Biotech,'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
